Home  About us  Contact
 

Wiley Interface Ltd (wiley + interface_ltd)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

Advances in the management of inflammatory bowel disease

FUTURE PRESCRIBER, Issue 2 2007
James Jupp BM MRCP Specialist Registrar in Gastroenterology
Inflammatory bowel disease is a common and complicated disorder that has a great impact on the lives of those affected. This review discusses the properties and uses of the treatments available and possible future advances in therapy. Copyright © 2007 Wiley Interface Ltd [source]

Combodart: combined therapy for moderate to severe BPH

PRESCRIBER, Issue 17 2010
MRPharmS, Steve Chaplin MSc
Combodart is a combination of tamsulosin and dutasteride licensed for the treatment of moderate to severe BPH. In our New products review Steve Chaplin presents the trial data relating to its efficacy and side-effects, and Professor Roger Kirby considers its advantages over an alpha-blocker or 5-alpha-reductase inhibitor taken alone. Copyright © 2010 Wiley Interface Ltd [source]

Guide to properties and efficacy of drugs used in migraine

PRESCRIBER, Issue 17 2010
Manuela Fontebasso MB ChB
It is essential to devise an individualised treatment plan in the management of migraine. Our Drug review considers the properties and efficacy of the various drugs used in treatment and prevention, followed by an analysis of prescription data and sources of further information. Copyright © 2010 Wiley Interface Ltd [source]

Is it effective to target treatment using just calculated CHD risk?

PRESCRIBER, Issue 14 2010
FRCPath, Tim Reynolds BSc
Statin prescribing for the primary prevention of CHD is based on risk calculated from long-term population data. Here, the author discusses the issues with the current risk models and suggests that money could be better spent on improved targeting through the use of a diagnostic test. Copyright © 2010 Wiley Interface Ltd [source]

Calcium-channel blockers: their properties and use in hypertension

PRESCRIBER, Issue 13 2010
Article first published online: 20 JUL 2010
A concise guide to the indications and properties of calcium-channel blockers and their current recommended place in the treatment of hypertension. Copyright © 2010 Wiley Interface Ltd [source]

Evaluation and recommended treatment of anaemia

PRESCRIBER, Issue 12 2010
Alastair Smith FRCP, FRCPath
The management of anaemia first requires an evaluation of the underlying cause of the disorder. Our Drug review considers the various oral and parenteral treatments available, followed by an analysis of prescription data and sources of further information. Copyright © 2010 Wiley Interface Ltd [source]

My views on medicines management past and present

PRESCRIBER, Issue 12 2010
Beryl Bevan
Chief pharmacist and experienced pharmaceutical adviser Beryl Bevan shares her views on medicines management and NHS restructuring over the past 20 years. Copyright © 2010 Wiley Interface Ltd [source]

Prucalopride (Resolor): new treatment for chronic constipation

PRESCRIBER, Issue 11 2010
MRPharmS, Steve Chaplin MSc
Prucalopride (Resolor) is a new treatment for women with chronic constipation who have not responded to conventional laxatives. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse effects and Drs Paul Blaker and Mark Wilkinson comment on its place in the treatment of constipation. Copyright © 2010 Wiley Interface Ltd [source]

The challenge of managing difficult-to-control epilepsy

PRESCRIBER, Issue 10 2010
Andrew Kelso MRCP
Our series on Prescribing challenges focuses on areas of therapeutics that can present a particular challenge in general practice. Here, the author addresses the problem of the patient with epilepsy who hasn't responded to two drugs in monotherapy. Copyright © 2010 Wiley Interface Ltd [source]

Vaccination in children: the UK immunisation programme

PRESCRIBER, Issue 10 2010
David Elliman FRCP, FRCPCH
Our series Prescribing in children gives practical advice for the management of childhood problems in general practice. Here, the authors describe the UK immunisation programme for children and the potential contraindications and adverse effects. Copyright © 2010 Wiley Interface Ltd [source]

Prescriber 1990,2010: key developments in drug treatment

PRESCRIBER, Issue 9 2010
FBPharmacolS, Gordon McInnes BSc
Our editorial consultants highlight the significant advances made in their therapeutic areas over the past 20 years. Here we look at developments in CVS and respiratory medicine and diabetes. Copyright © 2010 Wiley Interface Ltd [source]

Recommended micronutrient supplementation in pregnancy

PRESCRIBER, Issue 9 2010
Kate Duhig BSc, MB BS
Our series Prescribing in pregnancy provides a guide for GPs on what information to offer pregnant women about the risks and benefits of drug treatment. Here, the authors discuss the evidence and guidelines for prescribing dietary supplements during pregnancy. Copyright © 2010 Wiley Interface Ltd [source]

Treatment options in chronic obstructive pulmonary disease

PRESCRIBER, Issue 8 2010
Paul Walker BMedSci
Management of chronic obstructive pulmonary disease requires a true multidisciplinary approach, and therapies with a strong evidence base can bring benefits to patients. Our Drug review considers the available treatments and their efficacy, followed by sources of further information. Copyright © 2010 Wiley Interface Ltd [source]

Recommended management of nocturnal enuresis in children

PRESCRIBER, Issue 8 2010
Anthony Cohn MRCP, FRCPC
Our series Prescribing in children gives practical advice for successful management of childhood problems in general practice. Here, the author describes the three systems approach used in the treatment of nocturnal enuresis. Copyright © 2010 Wiley Interface Ltd [source]

Antibiotics for uncomplicated urinary tract infection in women

PRESCRIBER, Issue 7 2010
MB ChB, Sarah Thompson BSc
Most well women with uncomplicated urinary tract infection should respond to three days' treatment with a first-line antibiotic. Our Drug review describes the properties and side-effects of the recommended antibiotics, followed by sources of further information. Copyright © 2010 Wiley Interface Ltd [source]

Asthma treatment in pregnancy

PRESCRIBER, Issue 7 2010
Kate Emary BM BCh
Our series Prescribing in pregnancy provides guidance on what information to offer pregnant women about the risks and benefits of drug treatment. Here the authors discuss the course of asthma during pregnancy and the use and safety of asthma medications. Copyright © 2010 Wiley Interface Ltd [source]

Eslicarbazepine: new adjunctive treatment for partial epilepsy

PRESCRIBER, Issue 6 2010
MRPharmS, Steve Chaplin MSc
Eslicarbazepine acetate (Zebinix) is a new antiepileptic drug licensed as adjunctive treatment for partialonset seizures. In our New products review, Steve Chaplin presents the clinical data relating to efficacy and adverse effects, and Dr Andrew Kelso discusses its potential role in epilepsy treatment. Copyright © 2010 Wiley Interface Ltd [source]

Current treatment options in the management of severe pain

PRESCRIBER, Issue 6 2010
FFARCSI, FFPMRCA, William Campbell MD
Opioids are the most frequently used agents for severe nociceptive pain and should not be withheld in chronic noncancer pain. Our Drug review discusses the properties and efficacy of the opioids in common use, followed by an analysis of the prescription data and sources of further information. Copyright © 2010 Wiley Interface Ltd [source]

Drugs in type 2 diabetes: their properties and recommended use

PRESCRIBER, Issue 5 2010
Ian Campbell FRCP
There are now six classes of oral antidiabetic drugs and a new class of injectable GLP-1 agonists in the drug therapy of type 2 diabetes, with metformin remaining the cornerstone of treatment. Our Drug review considers their mode of action, properties and recommended use, followed by sources of further information and an analysis of prescription data. Copyright © 2010 Wiley Interface Ltd [source]

Ulipristal acetate: emergency contraception for up to five days

PRESCRIBER, Issue 5 2010
MRPharmS, Steve Chaplin MSc
Ulipristal acetate (EllaOne) is a new oral emergency contraceptive licensed for up to 120 hours following unprotected intercourse. In our New products review, Steve Chaplin presents the data relating to its efficacy and adverse effects and Dr Sharon Cameron discusses its role as an emergency contraceptive. Copyright © 2010 Wiley Interface Ltd [source]

Safer prescribing through education, IT and better systems

PRESCRIBER, Issue 4 2010
Steve Titmarsh BPharm
Steve Titmarsh reports on the British Pharmacological Society's winter symposium that focused on the causes of prescribing errors and how prescribing could be improved. Copyright © 2010 Wiley Interface Ltd [source]

The Kennedy report: appraising the value of innovative medicines

PRESCRIBER, Issue 3 2010
MRPharmS, Steve Chaplin MSc
Steve Chaplin outlines the recommendations made by Professor Sir Ian Kennedy in his recent report on the appraisal of innovative new medicines. Copyright © 2010 Wiley Interface Ltd [source]

11th annual NICE conference: innovation and value

PRESCRIBER, Issue 1-2 2010
Article first published online: 4 FEB 2010
NICE held their annual conference last month with the theme of innovation and value. We have highlighted a selection of the principal sessions. Copyright © 2010 Wiley Interface Ltd [source]

Liraglutide: new GLP-1 analogue for uncontrolled type 2 diabetes

PRESCRIBER, Issue 23-24 2009
MRPharmS, Steve Chaplin MSc
Liraglutide (Victoza) is a new GLP-1 analogue given by once-daily injection for the treatment of type 2 diabetes not controlled by mono- or dual therapy with oral agents. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Aftab Ahmad considers its potential place in therapy. Copyright © 2009 Wiley Interface Ltd [source]

Nongenital warts: clinical features and recommended treatment

PRESCRIBER, Issue 22 2009
Fawad Hussain MRCP
Viral warts are one of the most common cutaneous diseases, and treatment can be difficult and frustrating with frequent failures. In our Drug review we discuss the clinical presentations and treatment options, followed by sources of further information. Copyright © 2009 Wiley Interface Ltd [source]

Ustekinumab: new option for moderate-to-severe psoriasis

PRESCRIBER, Issue 21 2009
MRPharmS, Steve Chaplin MSc
Ustekinumab (Stelara), a novel biologic for the treatment of moderate-to-severe plaque psoriasis, targets interleukins rather than TNF-alpha. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Dr Downs discusses its place in psoriasis treatment. Copyright © 2009 Wiley Interface Ltd [source]

The NHS prescription charge: soon just for England

PRESCRIBER, Issue 19 2009
MRPharmS, Steve Chaplin MSc
Prescription charges in Scotland, Wales and Northern Ireland, but not England, are in the process of being abolished. Steve Chaplin discusses the implications and the proposed changes to the exemption system in England. Copyright © 2009 Wiley Interface Ltd [source]

GP guide to the management of haematological malignancies

PRESCRIBER, Issue 18 2009
FRCPath, Francis Matthey FRCP
Dr Matthey describes the GP's important role in diagnosis, referral, monitoring, treatment and supportive care in the management of patients with haematological malignancies. Copyright © 2009 Wiley Interface Ltd [source]

Malaria in children: bite avoidance and prophylaxis

PRESCRIBER, Issue 17 2009
Mary Gawthrop MA
Our series Prescribing in children gives practical advice for successful man-agement of childhood prob-lems in general practice. Here, the authors describe the mosquito bite avoidance and malaria prophylaxis options for this age group. Copyright © 2009 Wiley Interface Ltd [source]

Acne: guide to features and recommended management

PRESCRIBER, Issue 15-16 2009
Edward Seaton MA
Acne typically presents during puberty and can cause significant psychological morbidity and facial scaring. Our Drug review describes the underlying aetiology of acne development and the available treatments, followed by a review of the prescription data and sources of further information. Copyright © 2009 Wiley Interface Ltd [source]